DEF: IN8bio Seeks Shareholder Approval for Equity Plan Expansion

IN8bio, Inc. has filed a definitive proxy statement for its 2026 Annual Meeting of Stockholders, seeking approval for director elections, auditor ratification, and a significant increase in its equity incentive plan share reserve.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on May 7, 2026, at 9:00 a.m. Eastern Time.
• Key proposals include the election of two Class II directors (Peter Brandt and Corinne Epperly), the ratification of CohnReznick LLP as the independent registered public accounting firm for fiscal year 2026, and the approval of the Amended and Restated 2026 Equity Incentive Plan.
• The proposed 2026 Equity Incentive Plan seeks to increase the total number of shares of common stock issuable thereunder by 2,920,000 shares, extend the annual share increase period through 2037, establish a 20,000,000 share limit for Incentive Stock Options, and revise the annual share increase calculation to include common stock issuable upon settlement of pre-funded warrants.
• As of March 18, 2026, there were 9,847,089 shares of common stock outstanding and entitled to vote, and 9,620,002 pre-funded warrants outstanding.
• If the 2026 Plan is approved, a total of 4,054,937 shares will be initially available for grant, comprising 2,920,000 new shares, 146,670 shares remaining from the 2023 Plan, and any returning shares.
• Executive officer annual base salaries were increased effective January 1, 2026: William Ho to $644,500, Kate Rochlin to $535,100, and Patrick McCall to $489,100.
• The initial closing of the 2025 Private Placement on December 22, 2025, generated approximately $20.1 million in gross proceeds from the issuance of 5,127,029 common shares and 9,452,677 pre-funded warrants.
• A second closing for an additional approximately $20.1 million is contingent on achieving the INB-619 animal model data milestone by December 31, 2026, and meeting a specific stock price threshold or waiver.
• The 2024 Private Placement in October 2024 raised $11.2 million in net proceeds through the issuance of common stock, pre-funded warrants, and Series C Warrants.
• In April 2025, warrant exercises and exchanges generated approximately $1.9 million in gross proceeds, involving Series A and B warrants at reduced exercise prices.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the company is proactively addressing talent retention and corporate governance, the significant dilution from past and proposed equity issuances, coupled with the Nasdaq compliance issue and deeply underwater options, indicates underlying challenges that could impact shareholder value.

Positives

• The proposed 2026 Equity Incentive Plan is designed to attract, motivate, and retain qualified employees, non-employee directors, and consultants in the highly competitive life sciences industry.
• The inclusion of common stock issuable upon settlement of pre-funded warrants in the annual share increase calculation provides a more accurate reflection of the company's diluted share count for equity compensation purposes.
• The 2026 Plan incorporates corporate governance best practices, including a limit on non-employee director compensation, a clawback policy for awards, and a non-liberal definition of change in control.
• The Board unanimously recommends a vote FOR all proposals, indicating internal alignment and confidence in the proposed actions.

Negatives

• The significant increase in the equity incentive plan share reserve (2,920,000 new shares plus annual increases) represents potential future dilution for existing shareholders.
• The weighted-average exercise price of outstanding stock options ($26.56 as of March 18, 2026) is substantially higher than the current common stock closing price ($1.84), indicating a large number of underwater options that may not effectively incentivize current holders.
• The company received a Nasdaq notice regarding non-compliance with the minimum closing bid price requirement, posing a risk to its continued listing.
• Executive officer base salaries were increased effective January 1, 2026, after a previous reduction in September 2024, which could suggest fluctuating cost management strategies.

Risks

• Failure to attract and retain key talent if the equity incentive plan is not approved or if equity awards become less attractive due to stock price performance.
• Significant dilution of existing shareholder value due to the substantial increase in shares available for issuance under the 2026 Equity Incentive Plan and the exercise of outstanding warrants.
• Risk of delisting from The Nasdaq Capital Market due to non-compliance with the minimum closing bid price requirement.
• The Second Closing of the 2025 Private Placement, which would provide additional capital, is contingent on achieving the INB-619 animal model data milestone and a stock price threshold, introducing uncertainty regarding future funding.
• The company's reliance on equity awards for compensation may be less effective in retaining employees if the stock price remains low or declines further.

Future Outlook

The company anticipates continued growth in hiring and needs to offer competitive equity compensation to attract and retain talent in the highly competitive life sciences industry, particularly in the New York City area. The proposed equity plan increase is expected to cover needs for approximately two years. The second closing of the 2025 private placement is contingent on achieving the INB-619 animal model data milestone by December 31, 2026, and a specific stock price threshold or waiver.

Management Comments

• "Our continued ability to offer equity awards under the 2026 Plan is critical to our ability to attract, motivate and retain qualified employees, non-employee directors and consultants, particularly as we grow to support the research and development of our product candidates and in light of the highly competitive market for talent in which we operate."
• "We believe that providing an equity stake in the future success of our business encourages our employees to be highly motivated to achieve our long-term business goals and to increase stockholder value."
• "Any significant increase in cash compensation in lieu of equity awards would reduce the cash otherwise available for advancing the development of our product candidates."

Industry Context

StockSavvy.ai notes that the biotechnology sector, especially in major hubs like New York City, faces intense competition for skilled talent. The reliance on equity compensation, as highlighted by IN8bio, is a common strategy in this industry to align employee incentives with long-term shareholder value, particularly for companies in the research and development phase where cash flow may be constrained. The need for a substantial increase in the equity incentive plan reflects the ongoing demand for talent and the capital-intensive nature of drug development.

Comparison to Industry Standards

• IN8bio's burn rate of 2.5% for 2025 is relatively low compared to some early-stage biotechnology companies, which can often see burn rates exceeding 5-10% during intensive R&D phases, such as those observed in companies like CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT) during their early clinical development.
• The proposed 5% annual increase in the equity pool, including pre-funded warrants, is a common mechanism in the biotech industry to maintain a competitive compensation structure, similar to practices seen at companies like Moderna (MRNA) or BioNTech (BNTX) in their growth phases, though the specific percentage can vary.
• The non-employee director compensation limit of $700,000 (or $1,000,000 for new directors) is within the upper range of industry standards for small to mid-cap biotech firms, comparable to limits at companies like Sarepta Therapeutics (SRPT) or Alnylam Pharmaceuticals (ALNY), reflecting the specialized expertise required.
• The weighted-average exercise price of outstanding options ($26.56) significantly above the current stock price ($1.84) suggests a substantial portion of the existing equity incentives are underwater, a situation more pronounced than in many peer companies that have experienced recent stock price declines but typically not to this extent, such as those seen in smaller cap biotechs like Agenus (AGEN) or Geron (GERN) after clinical trial setbacks.

Management Changes

Corporate Governance

Related Party Transactions

• Participation in 2025 Private Placement: Directors and officers (Peter Brandt, William Ho, Kate Rochlin, Patrick McCall) and 5%+ beneficial owners (Alyeska Master Fund, L.P., Malcolm and Emily Charitable Remainder Unitrust 2010, where Emily Fairbairn is a trustee) collectively purchased shares and pre-funded warrants for an aggregate of $6,169,725.88.
• Participation in 2024 Private Placement: Directors and officers (Peter Brandt, William Ho, Kate Rochlin, Patrick McCall, Alan S. Roemer) and 5%+ beneficial owners (AIGH Investment Partners, LP, WVP Emerging Manager Onshore Fund, LLC, The Hewlett Fund LP, Alyeska Master Fund, L.P., Bios Clinical Opportunity Fund, LP, Malcolm and Emily Charitable Remainder Unitrust 2010) collectively purchased units for an aggregate of $6,100,000.
• Amended Series A Warrants: Certain outstanding ordinary warrants to purchase common stock, including those held by directors, officers, and 5%+ holders, were amended to reduce the exercise price from $37.50 to $13.50 per share and extend the termination date to October 4, 2025.
• Reduction in Salary of Chief Executive Officer: In connection with the 2024 Private Placement, William Ho's annual base salary was further reduced from $544,680 to $397,800, remaining in effect until December 31, 2025.
• Stock Purchase Agreement Amendment and Series B Warrant Amendment: In April 2025, an amendment to the 2024 Purchase Agreement was entered into, and Series B common stock purchase warrants held by certain holders were amended to reduce the exercise price from $45.00 to $13.50 per share.
• Warrant Exercises: In April 2025, certain holders, including directors and executive officers, exercised Series A and B warrants at reduced exercise prices of $5.532 or $5.352 per share.
• Warrant Exchanges: In April 2025, Bios Clinical Opportunity Fund, LP (a greater than 5% holder) and William Ho (CEO and director) exchanged Series A and B warrants for pre-funded warrants and a cash payment.
• Indemnification Agreements: The company has entered or intends to enter into separate indemnification agreements with its directors and certain executive officers.

Stakeholder Impact

• Shareholders will be directly impacted by the voting outcomes of the 2026 Annual Meeting, particularly regarding the significant expansion of the equity incentive plan, which could lead to further dilution.
• Employees, especially executive officers, will benefit from the expanded equity incentive plan and recent salary increases, which are intended to enhance talent attraction and retention in a competitive industry.
• Directors will continue to receive compensation through cash retainers and equity awards, with increased amounts effective January 1, 2026, reflecting their ongoing oversight responsibilities.
• The company's ability to advance its product candidates and achieve strategic goals is tied to its capacity to attract and retain key personnel, which the expanded equity plan aims to support.
• Creditors and investors in the recent private placements are impacted by the terms of those financings, including the contingent second closing and rights to participate in future equity raises, indicating ongoing capital needs.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders virtually on May 7, 2026, to vote on the proposed director elections, auditor ratification, and the Amended and Restated 2026 Equity Incentive Plan.
• If approved, the Amended and Restated 2026 Equity Incentive Plan will become effective, allowing for future equity awards.
• Monitor progress towards the INB-619 animal model data milestone, which is a condition for the Second Closing of the 2025 Private Placement.
• Continue efforts to regain compliance with Nasdaq's minimum bid price requirement to avoid potential delisting.
• File a Current Report on Form 8-K with the SEC within four business days after the Annual Meeting to disclose the final voting results.

Key Dates

Recommendation

The company is actively managing its corporate governance and talent retention through the proposed equity plan, which is a positive for long-term operational stability. However, the significant dilution from recent and proposed capital raises, the deeply underwater existing options, and the Nasdaq minimum bid price compliance issue present considerable headwinds. Investors should hold to monitor the execution of the INB-619 milestone, the impact of the new equity plan on talent retention, and progress on Nasdaq compliance before making further investment decisions.

Keywords

IN8bio, Proxy Statement, Equity Incentive Plan, Stock Options, Corporate Governance, SEC Filing, Biotechnology, Shareholder Meeting, Dilution, Executive Compensation, Warrants, Nasdaq Listing, Capital Raise